SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months, according to summary results revealed by developer Structure Therapeutics Monday.

SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is back with a new cut showing 6% weight loss in a phase 2a study. Structure ...

June 3 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street ...

A company's structure determines how different departments and employees interact with one another. That, in turn, determines how well the company operates. As your company grows, you may find that ...

AMES, Iowa – Edward Yu took note of the facts – nearly 2 million deaths each year, 9 million infected each year, developments of multidrug-resistant, extensively drug-resistant and now totally ...